Literature DB >> 22461365

MicroRNAs and stem cells: control of pluripotency, reprogramming, and lineage commitment.

Eva-Marie Heinrich1, Stefanie Dimmeler.   

Abstract

Stem cells hold great promise for regenerative medicine and the treatment of cardiovascular diseases. The mechanisms regulating self-renewal, pluripotency, and differentiation are not fully understood. MicroRNAs (miRs) are small noncoding RNAs controlling gene expression, either by inducing mRNA degradation or by blocking mRNA translation. The expression of miRs was shown to regulate various aspects of stem cell functions, including the maintenance and induction of pluripotency for reprogramming. In addition, some miRs control cell fate decisions. This review summarizes the role of miRs in reprogramming and embryonic stem cell self-renewal, and specifically addresses the regulation of cardiovascular cell fate decisions by miRs.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22461365     DOI： 10.1161/CIRCRESAHA.111.243394

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


  68 in total

Review 1.  MicroRNAs as novel regulators of stem cell fate.

Authors:  Eunhyun Choi; Eunmi Choi; Ki-Chul Hwang
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

2.  Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients.

Authors:  Samuel Robinson; Marie Follo; David Haenel; Maximilian Mauler; Daniela Stallmann; Lukas Andreas Heger; Thomas Helbing; Daniel Duerschmied; Karlheinz Peter; Christoph Bode; Ingo Ahrens; Marcus Hortmann
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

3.  MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines.

Authors:  Pasqualino de Antonellis; Lucia Liguori; Annarita Falanga; Marianeve Carotenuto; Veronica Ferrucci; Immacolata Andolfo; Federica Marinaro; Immacolata Scognamiglio; Antonella Virgilio; Giuseppe De Rosa; Aldo Galeone; Stefania Galdiero; Massimo Zollo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-26       Impact factor: 3.000

4.  RNA-binding protein Rbm47 binds to Nanog in mouse embryonic stem cells.

Authors:  Meghdad Yeganeh; Ehsan Seyedjafari; Farnaz Akbari Kamrani; Nasser Ghaemi
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

5.  Generation of intermediate porcine iPS cells under culture condition favorable for mesenchymal-to-epithelial transition.

Authors:  Shiqiang Zhang; Yanjie Guo; Yi Cui; Yajun Liu; Tong Yu; Huayan Wang
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739

Review 6.  Periosteum derived stem cells for regenerative medicine proposals: Boosting current knowledge.

Authors:  Concetta Ferretti; Monica Mattioli-Belmonte
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

7.  Induced multipotency in adult keratinocytes through down-regulation of ΔNp63 or DGCR8.

Authors:  Deepavali Chakravarti; Xiaohua Su; Min Soon Cho; Ngoc Hoang Bao Bui; Cristian Coarfa; Avinashnarayan Venkatanarayan; Ashley L Benham; Ramón E Flores González; Jennifer Alana; Weimin Xiao; Marco L Leung; Harina Vin; Io Long Chan; Arianexys Aquino; Nicole Müller; Hongran Wang; Austin J Cooney; Jan Parker-Thornburg; Kenneth Y Tsai; Preethi H Gunaratne; Elsa R Flores
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

Review 8.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

Review 9.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

Review 10.  Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease.

Authors:  Naomi M Hamburg; Nicholas J Leeper
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.